Retatrutide vs tirzepatide compared: triple vs dual agonist mechanism, half-life, the SURMOUNT and TRIUMPH trial data, the dysesthesia signal, and the head-to-head trial still pending.
Retatrutide and tirzepatide come from the same developer, share an albumin-binding, once-weekly design, and are often discussed as if one were simply the next version of the other. The real distinction is narrower and more interesting than that. Tirzepatide is a dual agonist with an approved-drug evidence base behind it. Retatrutide adds a third receptor target and has strong Phase 3 readouts, but it is still investigational. The two have not yet been compared directly in a published trial.
Tirzepatide is a 39-residue synthetic peptide built on the glucose-dependent insulinotropic polypeptide (GIP) scaffold and fitted with a C20 fatty-diacid chain for albumin binding. It agonizes two receptors, GIP-R and GLP-1R, and its profile is imbalanced: potency is high at GIP-R and comparatively lower at GLP-1R.
Retatrutide (LY3437943) is a single peptide that agonizes three receptors: GIP-R, GLP-1R, and the glucagon receptor (GCGR). The glucagon arm is what sets it apart. GLP-1 and GIP signalling act mainly on appetite and glucose-dependent insulin secretion. Glucagon-receptor activation is associated with increased energy expenditure and hepatic lipid oxidation. In principle, adding it alongside the incretin arms raises energy output while intake falls. A Phase 2a substudy in metabolic dysfunction–associated steatotic liver disease reported large reductions in liver fat. That result fits the hepatic role of the glucagon arm, but it does not prove the mechanism.
As with tirzepatide's GIP component, it is hard to say how much of the clinical effect comes from each receptor. Receptor-by-receptor attribution in humans is still an open research question.
| Retatrutide | Tirzepatide | |
|---|---|---|
| Class | Triple GIP / GLP-1 / glucagon receptor agonist | Dual GIP / GLP-1 receptor agonist |
| Elimination half-life | ~6 days | ~5 days |
| Administration in trials | Once weekly, subcutaneous | Once weekly, subcutaneous |
| Regulatory status | Investigational; not approved | Approved (Mounjaro, Zepbound) |
| Pivotal obesity trial | TRIUMPH-1: 80 weeks, n = 2,339 | SURMOUNT-1: 72 weeks, n = 2,539 |
| Mean weight change, top dose vs placebo | −28.3% (12 mg) vs −2.2% | −20.9% (15 mg) vs −3.1% |
| Distinctive safety signal | Dose-related dysesthesia | None comparable reported |
| Data maturity | Phase 2 plus Phase 3 toplines from 2025–2026 | Years of post-approval use and multiple completed Phase 3 programs |
These are cross-trial figures. The trials differ in duration, population, titration schedule and estimand, so the numbers do not support a head-to-head ranking.
Tirzepatide. SURMOUNT-1 (NEJM, 2022) randomized 2,539 adults with obesity or overweight and without diabetes to 5, 10 or 15 mg weekly or placebo for 72 weeks. Mean weight reductions were about 15.0%, 19.5% and 20.9%, compared with 3.1% on placebo. In SURMOUNT-5 (2025), tirzepatide was compared directly with semaglutide and produced 20.2% versus 13.7% weight loss at 72 weeks. Tirzepatide also has an active-comparator cardiovascular outcomes trial, SURPASS-CVOT. Our semaglutide vs tirzepatide comparison covers that trial in detail.
Retatrutide. The Phase 2 obesity trial (Jastreboff et al., NEJM, 2023) reported mean weight reductions of 22.8% at 8 mg and 24.2% at 12 mg after 48 weeks. Several Phase 3 readouts have followed, all published as sponsor topline press releases:
Full peer-reviewed publications for most of the Phase 3 program were still pending at the time of writing. Topline releases are a less complete source than published papers.
TRIUMPH-5 (NCT06662383) is randomizing about 800 adults with obesity to retatrutide or tirzepatide, with percentage weight change at 80 weeks as the primary endpoint. It is the first direct comparison of the two compounds, and its listed completion is late 2026. Until it reports, any "retatrutide beats tirzepatide" claim is an inference from separate trials, however plausible the gap looks.
Both compounds have adverse-event profiles dominated by gastrointestinal effects: nausea, diarrhea, constipation and vomiting. These are dose-related and concentrated in the escalation phase. In retatrutide's Phase 2 trial, starting at a lower dose (2 mg rather than 4 mg) partly reduced them.
Retatrutide has two additional signals:
Discontinuation due to adverse events in TRIUMPH-1 rose with dose, from 4.1% at 4 mg to 11.3% at 12 mg, against 4.9% on placebo. For the full tolerability picture, see retatrutide side effects and tirzepatide side effects.
As a literature question rather than a recommendation, the choice follows from what the study needs to isolate:
Is retatrutide just a stronger tirzepatide? No. The two are structurally distinct peptides with different receptor coverage. Retatrutide adds glucagon-receptor agonism to the GIP and GLP-1 activity the two share. Its trial effect sizes are larger, but no published trial has compared the two directly yet.
Has retatrutide been compared head-to-head with tirzepatide? Not in published data. TRIUMPH-5 (NCT06662383) is a randomized head-to-head trial with an 80-week primary endpoint, and its listed completion is late 2026.
Do they have similar half-lives? Yes, roughly. Retatrutide's half-life is about six days and tirzepatide's about five. Both support once-weekly administration in the published protocols.
What is dysesthesia, and does tirzepatide cause it? Dysesthesia is an abnormal, sometimes unpleasant skin sensation. It emerged as a dose-related signal in retatrutide's Phase 3 trials. It has not been reported as a comparable signal in tirzepatide's pivotal trials. Its mechanism with retatrutide is not yet established.
Where can I read more on each compound? See the retatrutide research overview, the tirzepatide research overview, and GLP-1 receptor agonists compared for the wider class. Product pages: retatrutide (10 mg, 20 mg, 30 mg, 15 mg pen) and tirzepatide (5 mg vial).
